Unibest
← Back to patent-cliff list

CAS 960404-62-0

L-proline compound with (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1)

Codes: DAPA-008

Application context (from source-drug indications)

Type 2 diabetesDapagliflozin Propanediol/Metformin HydrochlorideChronic renal impairmentDapagliflozin Propanediol MonohydrateHeart failureDapagliflozin Propanediol MonohydrateKidney diseaseDapagliflozin Propanediol MonohydrateType 1 diabetesDapagliflozin Propanediol MonohydrateType 2 diabetesDapagliflozin Propanediol MonohydratePolycystic ovary syndromeDapagliflozin Propanediol Monohydrate

Source drugs (routes using this intermediate)

DrugTierExpiry
Dapagliflozin Propanediol/Metformin HydrochlorideTier A — Act now2030
Dapagliflozin Propanediol MonohydrateTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.